ERBB2 and breast carcinoma: In order to gain detailed insight into ganetespib-mediated growth inhibition, particularly in ErbB2+ breast cancer cells, we treated BT474 and SKBR3 cells with ganetespib (250 nM) for 24 hours, followed by cell cycle analysis using flow cytometry.